172 related articles for article (PubMed ID: 34527623)
1. Hyperosmolar Hyperglycaemic State and Diabetic Ketoacidosis in Nivolumab-Induced Insulin-Dependent Diabetes Mellitus.
Saleh AO; Taha R; Mohamed SFA; Bashir M
Eur J Case Rep Intern Med; 2021; 8(8):002756. PubMed ID: 34527623
[TBL] [Abstract][Full Text] [Related]
2. Nivolumab-induced autoimmune diabetes mellitus presenting as diabetic ketoacidosis in a patient with metastatic lung cancer.
Godwin JL; Jaggi S; Sirisena I; Sharda P; Rao AD; Mehra R; Veloski C
J Immunother Cancer; 2017; 5():40. PubMed ID: 28515940
[TBL] [Abstract][Full Text] [Related]
3. New-onset insulin-dependent diabetes due to nivolumab.
Zaied AA; Akturk HK; Joseph RW; Lee AS
Endocrinol Diabetes Metab Case Rep; 2018; 2018():. PubMed ID: 29623210
[TBL] [Abstract][Full Text] [Related]
4. Presentation of new onset type 1 diabetes with diabetic ketoacidosis and hyperosmolar hyperglycaemia after a single dose of nivolumab and ipilimumab.
Stathi D; Hussain S; Crawley D; Karalliedde J
Endocrinol Diabetes Metab Case Rep; 2023 Aug; 2023(3):. PubMed ID: 37584383
[TBL] [Abstract][Full Text] [Related]
5. New onset diabetes with ketoacidosis following nivolumab immunotherapy: A case report and review of literature.
Delasos L; Bazewicz C; Sliwinska A; Lia NL; Vredenburgh J
J Oncol Pharm Pract; 2021 Apr; 27(3):716-721. PubMed ID: 32723064
[TBL] [Abstract][Full Text] [Related]
6. Nivolumab-induced autoimmune diabetes mellitus presenting as diabetic ketoacidosis in a patient with metastatic mucosal melanoma.
Goff CB; Plaxe SC; White W; Dasanu CA
J Oncol Pharm Pract; 2023 Jul; 29(5):1259-1263. PubMed ID: 36734125
[TBL] [Abstract][Full Text] [Related]
7. Combined checkpoint inhibitor therapy causing diabetic ketoacidosis in metastatic melanoma.
Changizzadeh PN; Mukkamalla SKR; Armenio VA
J Immunother Cancer; 2017 Dec; 5(1):97. PubMed ID: 29254501
[TBL] [Abstract][Full Text] [Related]
8. Rapid onset type-1 diabetes and diabetic ketoacidosis secondary to nivolumab immunotherapy: a review of existing literature.
Abdullah HMA; Elnair R; Khan UI; Omar M; Morey-Vargas OL
BMJ Case Rep; 2019 Aug; 12(8):. PubMed ID: 31451458
[TBL] [Abstract][Full Text] [Related]
9. Diabetic Ketoacidosis as a Delayed Immune-Related Event after Discontinuation of Nivolumab.
Mae S; Kuriyama A; Tachibana H
J Emerg Med; 2021 Mar; 60(3):342-344. PubMed ID: 33097350
[TBL] [Abstract][Full Text] [Related]
10. Painless Thyroiditis and Fulminant Type 1 Diabetes Mellitus in a Patient Treated with an Immune Checkpoint Inhibitor, Nivolumab.
Sakurai K; Niitsuma S; Sato R; Takahashi K; Arihara Z
Tohoku J Exp Med; 2018 Jan; 244(1):33-40. PubMed ID: 29343652
[TBL] [Abstract][Full Text] [Related]
11. Cemiplimab-Induced Hyperosmolar Hyperglycemic State With Concurrent Diabetic Ketoacidosis in a Patient Receiving Treatment for Cutaneous Squamous Cell Carcinoma.
Pyronneau A; Noronha K; Zucker A; Kennett R; Desai P
Cureus; 2024 May; 16(5):e60565. PubMed ID: 38764707
[TBL] [Abstract][Full Text] [Related]
12. Acute-onset diabetes mellitus with ketoacidosis in a nivolumab-treated patient with hepatocellular carcinoma.
Harsch IA; Konturek PC
Wiad Lek; 2018; 71(5):945-948. PubMed ID: 30176620
[TBL] [Abstract][Full Text] [Related]
13. Nivolumab-induced fulminant diabetic ketoacidosis followed by thyroiditis.
Tzoulis P; Corbett RW; Ponnampalam S; Baker E; Heaton D; Doulgeraki T; Stebbing J
Endocrinol Diabetes Metab Case Rep; 2018; 2018():. PubMed ID: 29576870
[TBL] [Abstract][Full Text] [Related]
14. A Rare Case of Severe Diabetic Ketoacidosis in a Patient With Metastatic Renal Cell Carcinoma Being Treated With Nivolumab.
Bazzi T; Gupta E; Mohamed A; Vashi M
Cureus; 2022 Sep; 14(9):e29537. PubMed ID: 36312693
[TBL] [Abstract][Full Text] [Related]
15. Multicentre analysis of hyperglycaemic hyperosmolar state and diabetic ketoacidosis in type 1 and type 2 diabetes.
Tittel SR; Sondern KM; Weyer M; Poeplau T; Sauer BM; Schebek M; Ludwig KH; Hammer F; Fröhlich-Reiterer E; Holl RW;
Acta Diabetol; 2020 Oct; 57(10):1245-1253. PubMed ID: 32488499
[TBL] [Abstract][Full Text] [Related]
16. Fulminant Type 1 Diabetes Mellitus Developed about Half a Year after Discontinuation of Immune Checkpoint Inhibitor Combination Therapy with Nivolumab and Ipilimumab: A Case Report.
Yaura K; Sakurai K; Niitsuma S; Sato R; Takahashi K; Arihara Z
Tohoku J Exp Med; 2021 Aug; 254(4):253-256. PubMed ID: 34373422
[TBL] [Abstract][Full Text] [Related]
17. Type 1 diabetes mellitus induced by PD-1 inhibitors in China: a report of two cases.
Luo J; Feng J; Liu C; Yang Z; Zhan D; Wu Y; Pan L; Zhang L
J Int Med Res; 2022 Sep; 50(9):3000605221121940. PubMed ID: 36171723
[TBL] [Abstract][Full Text] [Related]
18. New onset diabetes after nivolumab treatment.
Capitao R; Bello C; Fonseca R; Saraiva C
BMJ Case Rep; 2018 Jan; 2018():. PubMed ID: 29378735
[TBL] [Abstract][Full Text] [Related]
19. Nivolumab-induced type 1 diabetes mellitus as an immune-related adverse event.
Yilmaz M
J Oncol Pharm Pract; 2020 Jan; 26(1):236-239. PubMed ID: 30955467
[TBL] [Abstract][Full Text] [Related]
20. Durvalumab-induced diabetic ketoacidosis followed by hypothyroidism.
Patel S; Chin V; Greenfield JR
Endocrinol Diabetes Metab Case Rep; 2019 Dec; 2019():. PubMed ID: 31829972
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
